In the current study, the majority of the patients received a CD19-based reinfusion regimen with a median average dosing interval of 6.8 months (IQR 6.3–7.5) in MS patients and 6.4 months (IQR 6.0–7.8) in NMOSD patients. Here, CD19 is linked to myeloid sarcoma.